<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ancestry-Dependent Genomic Susceptibility to EGFR Mutagenesis - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-15</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-15</p>
                <p><strong>Name:</strong> Ancestry-Dependent Genomic Susceptibility to EGFR Mutagenesis</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why EGFR activating mutations in exons 18, 19, 20, and 21 are more common in East Asian lung cancer patients compared to other populations, based on the following results.</p>
                <p><strong>Description:</strong> East Asian populations harbor population-specific genomic structural variants and germline genetic architectures that increase susceptibility to acquiring somatic EGFR activating mutations during lung carcinogenesis. This manifests through: (1) elevated baseline frequency of EGFR copy number gains that create larger mutational targets and selective advantages, (2) possible differences in DNA repair pathway efficiency or mutational signature generation that allow EGFR mutations to be preferentially retained, and (3) rare but high-penetrance germline variants in specific populations that dramatically increase EGFR mutation risk. The theory posits that these ancestry-linked genetic factors create a permissive genomic landscape where EGFR mutations are both more likely to arise and more likely to be retained as dominant driver events, independent of environmental exposures when smoking and demographic factors are controlled.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: EGFR Copy Number Gain Ancestry Gradient</h3>
            <p><strong>Statement:</strong> The frequency of somatic EGFR copy number gains (≥3 copies) in lung adenocarcinoma follows an ancestry-dependent gradient, with East Asian patients showing approximately 2-2.5 fold higher rates (45-46%) compared to European-ancestry patients (20-21%), independent of smoking status and gender. This difference persists after multivariate adjustment (OR 2.36-2.43, p<0.01).</p>
            <p><strong>Domain/Scope:</strong> Applies to surgically resected lung adenocarcinomas with adequate tumor tissue for copy number analysis; measured by qPCR or similar quantitative methods with appropriate normalization; effect is independent of smoking status and gender when adjusted in multivariate models; applies across geographic locations (effect seen in immigrant populations, suggesting genetic rather than purely environmental basis).</p>
            <h4>Special Cases</h4>
            <ol>
                <li>May not apply to squamous cell carcinoma or other NSCLC histologies where EGFR biology differs</li>
                <li>Gradient likely follows genetic ancestry proportions in admixed populations rather than geographic residence</li>
                <li>Detection method (FISH vs qPCR vs NGS-based CNV calling) may affect absolute frequencies but relative gradient should persist</li>
                <li>May be modified by tumor purity and sampling heterogeneity in biopsy specimens</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>EGFR copy number gains present in 45.8% (76/166) of Asian vs 20.6% (28/136) of non-Asian lung adenocarcinoma patients; adjusted OR 2.36 (95% CI 1.30-4.28, p=0.005) and 2.43 (95% CI 1.17-5.07, p=0.017) after controlling for gender and smoking <a href="../results/extraction-result-282.html#e282.1" class="evidence-link">[e282.1]</a> </li>
    <li>Discrete copy number aberrations differ between East Asian and Western European populations, including chromosome 16p copy-number gains in East Asians and chromosome 19p losses in Western Europeans <a href="../results/extraction-result-258.html#e258.6" class="evidence-link">[e258.6]</a> </li>
    <li>Copy number gains occur frequently and the mutation-CNG inter-association is retained across Asian and non-Asian groups, suggesting structural genomic differences <a href="../results/extraction-result-258.html#e258.5" class="evidence-link">[e258.5]</a> </li>
    <li>gEGFR associated with never-smokers overall: 41.7% of never-smokers had gEGFR vs 29.9% of ever-smokers (P=0.046); gEGFR occurred more frequently in Asian subgroups across smoking/gender strata compared with corresponding non-Asian groups <a href="../results/extraction-result-282.html#e282.1" class="evidence-link">[e282.1]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While EGFR amplification and ethnic differences in mutation prevalence are individually documented, the systematic characterization of copy number gains as an ancestry-dependent predisposing factor that precedes and facilitates point mutation acquisition has not been established as a mechanistic theory explaining ethnic prevalence differences.</p>            <p><strong>What Already Exists:</strong> Copy number alterations in EGFR and other oncogenes are well-documented in lung cancer, and some population-level genomic structural differences have been described in cancer genomics literature.</p>            <p><strong>What is Novel:</strong> The specific quantification of a consistent ~2-2.5 fold ancestry-dependent gradient in EGFR copy number gains that persists after controlling for environmental and demographic factors, and the mechanistic hypothesis that this creates differential susceptibility to subsequent point mutations, represents a novel integration not previously characterized as a unified mechanism.</p>
        <p><strong>References:</strong> <ul>
    <li>Soh et al. (2015) Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma [First systematic documentation of CNG-ethnicity association with quantified effect sizes]</li>
    <li>Shi et al. (2015) Discrete copy number aberrations differing by ethnicity [Documented broader genomic structural differences between populations]</li>
    <li>Midha et al. (2015) EGFR mutation incidence in non-small-cell lung cancer: mutMapII [Documented mutation frequency gradients but not CNG mechanisms]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Co-occurrence of EGFR Copy Number Gains and Point Mutations</h3>
            <p><strong>Statement:</strong> In lung adenocarcinoma, EGFR copy number gains and activating point mutations co-occur at rates suggesting non-random association, with copy number gains enriched in cases that also harbor EGFR point mutations. This co-occurrence pattern is preserved across ancestries but the baseline frequencies of both alterations differ by ancestry, creating a multiplicative effect on EGFR-driven tumor prevalence.</p>
            <p><strong>Domain/Scope:</strong> Applies to lung adenocarcinomas with comprehensive genomic profiling including both copy number and mutation analysis; requires adequate tumor purity (typically >20-30%) for accurate dual detection; effect measurable when both alterations are assessed in the same tumor specimens.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Approximately 40-50% of EGFR-mutant cases lack detectable copy number gains, indicating CNG is not necessary for mutation occurrence</li>
                <li>May be confounded by tumor heterogeneity where different clones harbor different alterations</li>
                <li>Sequential acquisition order (CNG then mutation vs mutation then CNG) not clearly established</li>
                <li>Effect size of co-occurrence may vary by specific mutation type (exon 19 deletions vs L858R vs rare mutations)</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>EGFR copy number gains are enriched in cases with EGFR mutations, implying selection for combined activation; ethnicity remains significant predictor of both alterations after adjustment for smoking and gender <a href="../results/extraction-result-282.html#e282.1" class="evidence-link">[e282.1]</a> </li>
    <li>Copy number gains and point mutations in EGFR co-occur and the mutation-CNG inter-association is retained across Asian and non-Asian groups, but with different baseline frequencies <a href="../results/extraction-result-258.html#e258.5" class="evidence-link">[e258.5]</a> </li>
    <li>Among tested patients with available EGFR status: 209/575 = 36.3% EGFR-positive overall; pattern of EGFR activation through both mutations and copy gains observed in Korean cohort <a href="../results/extraction-result-308.html#e308.0" class="evidence-link">[e308.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While individual observations of co-occurrence exist, the mechanistic theory linking ancestry-dependent copy number variation to ethnic differences in point mutation prevalence through a predisposition model represents novel theoretical synthesis not previously articulated.</p>            <p><strong>What Already Exists:</strong> Co-occurrence and mutual exclusivity patterns of oncogenic alterations are well-studied in cancer genomics, and the general concept that copy number gains can cooperate with point mutations is established.</p>            <p><strong>What is Novel:</strong> The specific hypothesis that ancestry-dependent differences in EGFR copy number gains act as a predisposing factor that modulates the probability of acquiring point mutations, thereby explaining ethnic prevalence differences through a two-step genomic mechanism, is a novel mechanistic integration.</p>
        <p><strong>References:</strong> <ul>
    <li>Soh et al. (2015) Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma [Documented CNG-mutation co-occurrence patterns]</li>
    <li>Vogelstein et al. (2013) Cancer genome landscapes [General framework for understanding cooperation of genetic alterations, but not ancestry-specific]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Germline Predisposition Modulates Somatic EGFR Mutation Risk</h3>
            <p><strong>Statement:</strong> Rare germline variants in tumor suppressor genes (particularly TP53 R337H) or potentially in DNA repair pathway genes can dramatically increase the probability of acquiring somatic EGFR activating mutations in lung tumors, with reported prevalence reaching 89% in carriers vs 30-50% in non-carriers in the same populations. Population-specific founder variants create regional hotspots of elevated EGFR mutation prevalence that contribute to geographic variation.</p>
            <p><strong>Domain/Scope:</strong> Applies to lung cancer patients carrying specific germline variants, most clearly demonstrated for TP53 R337H in Southeastern Brazil; effect is strongest in never-smokers and in adenocarcinoma histology where germline predisposition effects are not masked by high mutational burden from smoking; rare variant frequencies (typically <1-5% carrier rate) limit population-level impact despite strong individual-level effects; requires germline sequencing to detect.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>TP53 R337H is a founder mutation specific to Southeastern Brazilian population with Portuguese ancestry</li>
                <li>Effect may be strongest in never-smokers where competing smoking-related mutational processes are absent</li>
                <li>Rare variant frequencies mean population attributable risk is low even with high individual relative risk</li>
                <li>Germline EGFR mutations (T790M, V843I) cause familial clustering but are extremely rare</li>
                <li>May apply to other DNA damage response genes but evidence is limited</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Germline TP53 p.R337H founder mutation in Southeastern Brazil associated with very high rate of somatic EGFR mutations: up to 89% EGFR mutation prevalence in lung tumors of carriers compared to typical Brazilian rates <a href="../results/extraction-result-257.html#e257.4" class="evidence-link">[e257.4]</a> </li>
    <li>Rare inherited germline EGFR mutations (T790M, V843I) identified in familial cases and can associate with familial clustering of EGFR-mutant NSCLC, representing a genetic predisposition mechanism <a href="../results/extraction-result-226.html#e226.1" class="evidence-link">[e226.1]</a> </li>
    <li>In Southeastern Brazil, the TP53 p.R337H founder germline variant is linked with extremely high prevalence (reported up to 89% in one cited study) of somatic EGFR mutations among carriers, suggesting germline predisposition can strongly bias somatic driver landscapes <a href="../results/extraction-result-257.html#e257.4" class="evidence-link">[e257.4]</a> </li>
    <li>Review notes rare germline EGFR alleles (T790M, V843I) have been identified that can predispose to familial EGFR-mutant lung cancer through two-hit-like model <a href="../results/extraction-result-226.html#e226.1" class="evidence-link">[e226.1]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> While germline TP53 mutations and their cancer predisposition are well-known, the specific selective effect on EGFR as a somatic driver (reaching 89% vs typical 30-50%) and its role in geographic variation represents a novel observation that has not been mechanistically explained or widely recognized.</p>            <p><strong>What Already Exists:</strong> Germline predisposition to cancer through TP53 mutations is well-established (Li-Fraumeni syndrome), and the concept of germline variants influencing somatic mutation patterns is recognized in cancer genetics.</p>            <p><strong>What is Novel:</strong> The specific and dramatic association between germline TP53 variants and preferential acquisition of somatic EGFR (rather than other oncogene) mutations, and the recognition that this mechanism contributes to geographic variation in EGFR prevalence, represents a novel gene-gene interaction not previously characterized mechanistically.</p>
        <p><strong>References:</strong> <ul>
    <li>Malkin et al. (1990) Germ line p53 mutations in a familial syndrome [Li-Fraumeni syndrome foundation]</li>
    <li>Achatz et al. (2007) The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families [TP53 R337H founder mutation]</li>
    <li>Studies cited in e257.4 on Brazilian TP53 R337H and EGFR [Specific EGFR-TP53 association]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: Persistence of Ancestry Effects Across Environments</h3>
            <p><strong>Statement:</strong> EGFR mutation prevalence differences by ancestry persist in immigrant populations and across different geographic environments, with Asian immigrants to Western countries maintaining high EGFR mutation rates (35-47% in studies) similar to their countries of origin rather than converging to local (Western) rates (10-15%), supporting genetic architecture over environmental causation as the primary driver of ethnic differences.</p>
            <p><strong>Domain/Scope:</strong> Applies to lung adenocarcinoma in immigrant populations with adequate generation time in new environment (typically first or second generation); effect most clearly measured in never-smokers where smoking confounding is eliminated; requires comparison groups with documented ancestry and immigration status; applies when comparing similar clinical populations (stage, histology, selection criteria).</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Heavy smokers may show partial convergence as smoking-related mutations can mask genetic predisposition</li>
                <li>Admixed populations show intermediate frequencies suggesting genetic dosage effect</li>
                <li>Multi-generational effects difficult to measure due to sample size limitations</li>
                <li>Selection bias in immigrant populations (healthy migrant effect) could confound but would be expected to reduce rather than maintain differences</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>In France, Asian patients (N=39, 1.8% of cohort) had 36.1% EGFR mutation prevalence compared to 10.2% in Caucasians and 9.3% in Africans, despite living in the same environment; multivariate HR for Asia vs Europe = 5.65 (95% CI 2.67-12.0, p<0.0001) <a href="../results/extraction-result-262.html#e262.0" class="evidence-link">[e262.0]</a> </li>
    <li>In Los Angeles multi-ethnic cohort, Asian patients (N=142) had 47.2% EGFR mutation prevalence vs 23.3% in Hispanic patients, with adjusted OR 0.31 (95% CI 0.16-0.58) for Hispanic vs Asian after controlling for site, age, gender, and smoking <a href="../results/extraction-result-258.html#e258.0" class="evidence-link">[e258.0]</a> </li>
    <li>Multi-country cohort (Japan, US, Australia, Canada) showed Asian patients had 38% EGFR mutation prevalence vs 10.3% in non-Asian patients; adjusted OR 4.76-4.94 after controlling for gender and smoking; immigrant Asian cases maintain EGFR patterns <a href="../results/extraction-result-282.html#e282.0" class="evidence-link">[e282.0]</a> </li>
    <li>Authors argue immigrant Asian cases in Western countries retain high EGFR alteration frequency, suggesting environmental factors (as measured by geography/immigration) are unlikely to fully explain ethnic differences <a href="../results/extraction-result-282.html#e282.0" class="evidence-link">[e282.0]</a> </li>
    <li>Asian immigrants to Western countries show EGFR mutation rates that do not converge toward European rates, supporting genetic architecture over environment <a href="../results/extraction-result-262.html#e262.0" class="evidence-link">[e262.0]</a> <a href="../results/extraction-result-258.html#e258.0" class="evidence-link">[e258.0]</a> </li>
    <li>In New Zealand, Asian patients showed 51.8% EGFR prevalence vs 16.5% in New Zealand Europeans and 10.9% in Māori, supporting ancestry over environment <a href="../results/extraction-result-257.html#e257.2" class="evidence-link">[e257.2]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> While the migrant study design is established, the comprehensive application to EGFR mutations with consistent findings across multiple settings and the integration into a genetic architecture theory is novel and not previously synthesized as a coherent evidence base for genetic causation.</p>            <p><strong>What Already Exists:</strong> Migrant studies are a standard epidemiological approach to distinguish genetic from environmental factors, and persistence of ethnic differences in immigrant populations has been noted anecdotally in cancer genetics.</p>            <p><strong>What is Novel:</strong> The systematic documentation across multiple immigrant populations (French Asians, US/Los Angeles Asians, New Zealand Asians) showing persistent 3-5 fold EGFR mutation prevalence differences with quantified effect sizes after controlling for environment, combined with the theoretical interpretation as evidence for genetic architecture, represents novel synthesis.</p>
        <p><strong>References:</strong> <ul>
    <li>Saffroy et al. (2017) Impact of country of birth on genetic testing [French immigrant cohort]</li>
    <li>Hsu et al. (2022) Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC [Los Angeles multi-ethnic cohort]</li>
    <li>Blot & Tarone (2015) Lung cancer following migration [General framework for migrant studies in lung cancer]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>In multi-ethnic cohorts with quantitative genetic ancestry data (genome-wide SNP arrays), EGFR mutation prevalence should show continuous correlation with proportion of East Asian ancestry, with each 10% increase in East Asian ancestry associated with approximately 2-3% absolute increase in EGFR mutation prevalence in lung adenocarcinoma.</li>
                <li>East Asian patients with lung adenocarcinoma who have EGFR copy number gains but no baseline detectable EGFR point mutations should show higher rates of EGFR mutation emergence during longitudinal follow-up or under selective pressure (e.g., liquid biopsy monitoring during chemotherapy) compared to non-Asian patients with copy number gains, if copy number creates mutational vulnerability.</li>
                <li>In families with Li-Fraumeni syndrome (germline TP53 mutations) across different ancestries, the prevalence of EGFR-mutant lung cancers should be elevated compared to sporadic cases within the same ancestry, and should show the same ancestry gradient (higher in Asian Li-Fraumeni families vs European Li-Fraumeni families) as seen in sporadic cases.</li>
                <li>Whole-genome sequencing of lung adenocarcinomas from East Asian vs European patients should reveal differences in EGFR locus chromatin accessibility, replication timing, or local mutation density that correlate with EGFR copy number status and mutation presence.</li>
                <li>In prospective cohort studies, EGFR copy number gains detected in premalignant lesions or carcinoma in situ should predict higher risk of progression to invasive EGFR-mutant adenocarcinoma in East Asian patients compared to European patients with similar premalignant copy gains.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>If EGFR copy number is experimentally equalized across ancestry-derived cell lines (using CRISPR-based copy number manipulation), subsequent EGFR point mutation rates under standardized mutagenic stress should either: (a) equalize if CNG is sufficient, or (b) remain ancestry-dependent if additional cell-intrinsic factors exist. This would definitively test mechanism.</li>
                <li>Genome-wide association studies (GWAS) specifically comparing EGFR-mutant vs EGFR-wild-type lung adenocarcinoma cases (rather than cancer vs controls) should identify ancestry-informative loci near DNA repair genes (e.g., BRCA1/2, PARP, MMR genes), EGFR regulatory regions, or chromatin structure genes that differ between East Asian and European populations, if germline genetic architecture contributes.</li>
                <li>Single-cell DNA sequencing of early-stage (in situ or minimally invasive) lung adenocarcinomas should reveal whether East Asian patients have: (a) higher rates of subclonal EGFR mutations even in non-EGFR-driven tumors (supporting increased mutability), or (b) similar subclonal rates but stronger positive selection for EGFR clones (supporting selection model).</li>
                <li>If comprehensive germline whole-exome sequencing of large East Asian and European lung cancer cohorts reveals significant differences in rare variant burden in specific DNA repair pathway genes or EGFR regulatory factors, this would strongly support germline architecture; if no differences are found, this would challenge the germline component of the theory.</li>
                <li>Experimental humanized mouse models where human lung epithelial cells from East Asian vs European donors are transplanted and exposed to standardized carcinogens should reveal whether cells develop EGFR mutations at different rates in identical environments, definitively testing cell-autonomous genetic effects.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If EGFR copy number gains are experimentally induced to equal levels in East Asian-derived and European-derived lung cell lines, and subsequent EGFR point mutation rates equalize under standardized conditions, this would suggest copy number is sufficient and no additional ancestry-specific factors are required, simplifying but also limiting the theory.</li>
                <li>If comprehensive germline sequencing (whole genome, not just exome) of large, well-matched East Asian and European lung cancer cohorts reveals no significant differences in: (a) rare variant burden in DNA repair genes, (b) regulatory variants near EGFR, or (c) structural variants affecting EGFR locus stability, this would challenge the germline genetic architecture component of the theory.</li>
                <li>If longitudinal studies of East Asian immigrants to Western countries over multiple generations (first, second, third generation) show progressive convergence of EGFR mutation prevalence toward local European rates, this would support environmental factors overriding genetic predisposition and challenge the persistence prediction.</li>
                <li>If single-cell sequencing studies show that subclonal EGFR mutation rates are equivalent across ancestries in early lesions, but that positive selection coefficients for EGFR-mutant clones are stronger in East Asian patients (due to microenvironment or immune factors), this would shift the mechanism from mutation susceptibility to selection, contradicting the mutational vulnerability hypothesis.</li>
                <li>If experimental induction of EGFR copy number gains in non-Asian cell lines increases their EGFR point mutation rate to levels matching or exceeding Asian cell lines with naturally occurring copy gains, and this effect is independent of any other genomic context, this would suggest copy number is not just sufficient but dominant, making other ancestry-specific factors less important.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>The specific molecular mechanism by which EGFR copy number gains would increase point mutation rates (e.g., through replication stress and fork stalling, altered DNA repair recruitment to multi-copy loci, or increased chromatin accessibility) is not detailed in the evidence and remains speculative. </li>
    <li>Why certain subgroups within East Asia show such dramatic variation (e.g., Kinh Vietnamese at 64.2% vs Indians at 21.9% in PIONEER study, or regional China variation) despite genetic relatedness is not explained by copy number or known germline variants alone, suggesting additional unidentified factors. <a href="../results/extraction-result-230.html#e230.1" class="evidence-link">[e230.1]</a> <a href="../results/extraction-result-258.html#e258.1" class="evidence-link">[e258.1]</a> <a href="../results/extraction-result-253.html#e253.3" class="evidence-link">[e253.3]</a> </li>
    <li>The mechanism by which TP53 germline mutations specifically predispose to EGFR (rather than other receptor tyrosine kinases like MET, ALK, ROS1, or other oncogenes) somatic mutations is not explained in available evidence; molecular pathway linking TP53 loss to EGFR-specific mutagenesis unknown. <a href="../results/extraction-result-257.html#e257.4" class="evidence-link">[e257.4]</a> </li>
    <li>Several studies note detection method differences (PCR vs NGS, FISH vs qPCR for CNG) can affect measured prevalence, but the theory does not account for whether ancestry-dependent differences in mutation spectrum or copy number distribution might interact with detection methods to bias apparent ethnic differences. <a href="../results/extraction-result-269.html#e269.2" class="evidence-link">[e269.2]</a> <a href="../results/extraction-result-220.html#e220.0" class="evidence-link">[e220.0]</a> </li>
    <li>The theory does not explain the strong female predominance of EGFR mutations (approximately 1.5-2 fold higher in females across ancestries), though female enrichment is consistent across ethnic groups and thus doesn't explain ethnic differences per se. <a href="../results/extraction-result-225.html#e225.0" class="evidence-link">[e225.0]</a> <a href="../results/extraction-result-233.html#e233.0" class="evidence-link">[e233.0]</a> <a href="../results/extraction-result-262.html#e262.0" class="evidence-link">[e262.0]</a> <a href="../results/extraction-result-258.html#e258.0" class="evidence-link">[e258.0]</a> </li>
    <li>Regional variation within China in exon-type predominance (exon 19 deletions vs L858R varying between Taiwan, Guangdong, Beijing) is difficult to explain by ancestry-dependent genomic architecture if these populations are genetically similar. <a href="../results/extraction-result-253.html#e253.3" class="evidence-link">[e253.3]</a> </li>
    <li>The observation that Uighur populations (intermediate ancestry between European and East Asian) show intermediate EGFR prevalence (15.8%) but different exon-type distribution than Han Chinese suggests complexity beyond simple ancestry gradient. <a href="../results/extraction-result-253.html#e253.0" class="evidence-link">[e253.0]</a> </li>
    <li>Some squamous cell carcinoma cases in East Asian cohorts show EGFR mutations (11.1% in Korean cohort, higher in never-smokers), which is rarely seen in Western cohorts, suggesting the ancestry effect may extend beyond adenocarcinoma despite squamous predominance of smoking-related tumors. <a href="../results/extraction-result-308.html#e308.0" class="evidence-link">[e308.0]</a> </li>
    <li>African ancestry populations show variable and intermediate EGFR prevalence (African women in France showing 29.3% prevalence similar to Asians, but other African cohorts lower), not easily explained by genomic architecture theory without additional data on African population genetic structure. <a href="../results/extraction-result-262.html#e262.0" class="evidence-link">[e262.0]</a> <a href="../results/extraction-result-257.html#e257.5" class="evidence-link">[e257.5]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>